Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. Pipelines are of prime importance as far as pharma/biotech companies are concerned. These companies spend a significant amount in advancing their pipelines.

Novo Nordisk’s (NVO - Analyst Report) diabetes pipeline includes semaglutide, IDegLira, Tresiba and Ryzodeg. All four candidates are for the treatment of type II diabetes.

Novo Nordisk has a strong presence in the diabetes care market with one of the broadest diabetes portfolios in the industry. Novo Nordisk stated that it commands a 27% market share of the total diabetes care market.

Recently, Novo Nordisk joined forces with Zosano Pharma, Inc. to develop a new transdermal presentation of semaglutide, once weekly GLP-1 analogue. Under this deal, semaglutide will be administered once weekly using Zosano's microneedle patch system for the treatment of type II diabetes.

Firstly, Zosano and Novo Nordisk will carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system.

Zosano granted Novo Nordisk an exclusive global license to develop and commercialize semaglutide using Zosano's microneedle patch system. Novo Nordisk will market all products under this deal, subject to approval.

Potential payments to Zosano could total above $60 million for the first product and $55 million for every additional product. Zosano is also eligible to receive royalties on sales of products and will receive development support, as well as reimbursement of all development and manufacturing costs.

We expect the company’s diabetes candidates to continue to make progress and contribute to growth.

Novo Nordisk carries a Zacks Rank #4 (Sell). Some better-ranked players in the pharma industry include Actelion Ltd. (ALIOF), Endocyte Inc. (ECYT - Snapshot Report) and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report). All three stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%